<DOC>
	<DOCNO>NCT02068352</DOCNO>
	<brief_summary>The purpose study investigate effectiveness safety 2 concentration OPA-15406 compare vehicle subject atopic dermatitis .</brief_summary>
	<brief_title>A Study Evaluate Effectiveness Safety Topical Ointment Treat Subjects With Atopic Dermatitis</brief_title>
	<detailed_description>Atopic dermatitis disease mainly characterize pruritic eczema , patient disease experience repeat exacerbation remission . . Therapeutic guideline disease , currently develop many country , recognize AD chronic eczema accompany physiological dysfunction skin inflammation cause various nonspecific stimulus specific allergen . OPA 15406 type-4 phosphodiesterase ( PDE4 ) inhibitor . PDE4 inhibitor think useful allergic inflammatory disease . This Phase 2 dose range study evaluate efficacy two concentration OPA 15406 ointment compare vehicle , administer topically twice daily subject mild moderate AD .</detailed_description>
	<mesh_term>Dermatitis</mesh_term>
	<mesh_term>Dermatitis , Atopic</mesh_term>
	<mesh_term>Eczema</mesh_term>
	<criteria>Subjects 1070 year age Diagnosis atopic dermatitis ( AD ) History AD least 3 year AD affect great equal 5 % less equal 40 % total Body Surface Area ( BSA ) Baseline Investigator 's Global Assessment Disease Severity score 2 ( mild ) 3 ( moderate ) select treatment area ( ) Contact atopic dermatitis flare within 28 day Baseline ( Day 1 ) visit . Concurrent diseases/conditions history diseases/conditions select treatment area ( ) may impact study assessment .</criteria>
	<gender>All</gender>
	<minimum_age>10 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>Atopic Dermatitis , Eczema</keyword>
</DOC>